Citius Pharmaceuticals Inc (CTXR) 0.7825 $CTXR Looking

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Citius Pharmaceuticals Inc (CTXR) 0.7825 $CTXR

Looking for "Firsts" in Health Care? Check Out Upcoming Catalysts for Citius Pharmaceuticals
PR Newswire - Thu Aug 04, 9:13AM CDT
By Sara Bowman, Senior Staff Writer, Online Media Group, Inc.

Citius Pharmaceuticals Provides Shareholder Update on Recent Achievements
PR Newswire - Mon Aug 01, 6:00AM CDT
Citius Pharmaceuticals, Inc. ("Citius" (OTC BB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, today provided shareholders with an update regarding the company's recent more notable achievements.

OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
PR Newswire - Tue May 31, 5:49PM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York. The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The Conference will feature presentations by CEOs and CFOs from various industry sectors, expert panels, and the opportunity to meet with management of presenting companies on a one-on-one basis.
LTEA: 5.24 (+0.23)

Citius Pharmaceuticals Completes Acquisition of Leonard-Meron Biosciences
PR Newswire - Mon Apr 04, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR) ("Citius" today announced completion of the acquisition of Leonard-Meron Biosciences, Inc. ("LMB". Pursuant to the acquisition, Citius acquired all of the outstanding shares of LMB common stock in exchange for shares of Citius common stock.

Citius Pharmaceuticals Announces Significant Equity Investment from Chairman and CEO
PR Newswire - Wed Mar 23, 6:00AM CDT
Citius Pharmaceuticals, Inc.,"Citius" (OTCQB: CTXR) or the "Company", today announced that Chairman and CEO Leonard Mazur has purchased 5 million of its restricted shares from the Company for $3 million dollars. This substantial investment will enable the Company to continue its development efforts across its product portfolio, and to build the infrastructure necessary to support multiple product development efforts.

Citius Pharmaceuticals Signs Letter of Intent to Acquire Leonard Meron Biosciences
PR Newswire - Mon Mar 07, 6:00AM CST
Citius Pharmaceuticals, Inc.,"Citius" (OTCQB: CTXR) today announced that the Company has entered into a non-binding letter of intent to acquire all of the outstanding shares of Leonard Meron Biosciences, Inc. (LMB). LMB's lead drug candidate, Mino-Lok(TM), is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, or CRBSIs. Mino-Lok(TM) is a patent-protected, novel solution containing minocycline, edetate (disodium EDTA), and ethyl alcohol, which act to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter. Mino-Lok(TM) is entering phase 3 trials after demonstrating safety in its phase 2b trial conducted at the MD Anderson Cancer Center in Houston. Recently, the U.S. Food and Drug Administration (FDA) granted a Qualified Infectious Disease Product (QIDP) designation for Mino-Lok. Receiving QIDP designation means that Mino-Lok(TM) is now eligible for Fast Track designation, Priority Review for development, and a five-year extension of market exclusivity. The Company believes that the commercial target for Mino-Lok(TM) represents a significant opportunity in the multi-billion, critical care market.

Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids
PR Newswire - Mon Feb 01, 6:00AM CST
Citius Pharmaceuticals, Inc. (OTCQB: CTXR) today announced top line data from the first Phase 2a clinical trial of hydrocortisone acetate (HC) and lidocaine hydrochloride (L) as single agents and in combination (HC+L) in patients with grade I and II hemorrhoids. Citius' hydrocortisone and lidocaine cream is targeting to become the first FDA -approved prescription product to treat hemorrhoids in the U.S.

Citius Pharmaceuticals, Inc. Announces Appointment of Mr. Suren Dutia to Its Board of Directors
PR Newswire - Thu Oct 08, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company" announced today that it has appointed Mr. Suren Dutia to the board of directors effective October 8, 2015.

Citius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors
PR Newswire - Tue Oct 06, 6:00AM CDT
Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company" announced today that it has appointed Mr. Myron Holubiak to the board of directors effective October 1, 2015.
BIOS: 2.60 (-0.01), ASMB: 6.06 (+0.17)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 99

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 446

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Luxurious Mark Lane Apartments in Naples, FL

Updated Category News Views 205

Explore the Luxurious Mark Lane Apartments Mark Lane Apartments is a remarkable new residential community that has quickly established itself in the real estate market. A Class A+ Trophy Asset This impressive four-story concrete block building is a true trophy asset, featuring 286 spacious units, each averaging 1,050 square feet. The complex is situated on a generous...

Continue Reading
Major Revenue Surge: POP Culture Group's Impressive FY2025 Results

Updated Category News Views 226

POP Culture Group Achieves Record Revenue in FY2025 In a remarkable financial breakthrough, POP Culture Group Co., Ltd. (Nasdaq: CPOP) has announced its fiscal year 2025 results, showcasing an incredible revenue surge that exceeded $100 million for the first time. This milestone represents a significant leap, with revenue increasing by 127% compared to the previous fiscal...

Continue Reading
Jericho Wholesale and Shell Unite for Breast Cancer Awareness

Updated Category News Views 184

Jericho Wholesale and Shell Join Forces for a Cause Jericho Wholesale is proud to partner with Shell in the initiative Power Up for Pink Aid this October during Breast Cancer Awareness Month. This exciting campaign aims to assist underserved breast cancer patients and their families through vital financial support while raising awareness for the disease. What is Power Up...

Continue Reading
PMGC Holdings Implements Strategic Reverse Stock Split for Growth

Updated Category News Views 119

PMGC Holdings Announces Reverse Stock Split PMGC Holdings Inc. (NASDAQ: ELAB), based in Newport Beach, California, has recently unveiled an important strategic decision to carry out a 1-for-7 reverse stock split effective soon. This move reflects the company’s commitment to maintaining its compliance with Nasdaq’s listing requirements, which is essential for...

Continue Reading
Lynch Carpenter Takes Action on Anne Arundel Data Incident

Updated Category News Views 270

Lynch Carpenter's Response to the Data Breach Incident Recently, a cybersecurity incident was reported by Anne Arundel Dermatology, revealing that a significant breach of personal data has occurred. This disturbing event is said to have affected the personal information of numerous individuals, raising substantial concerns about data privacy. Details of the Cybersecurity...

Continue Reading